Evidence map›Paper›PMID 41581886›Full record

ArticleThe Journal of biological chemistry2026

The stress-activated kinase p38 mediates non-canonical activation of Src and tyrosine phosphorylation of the adapter protein TAB1.

Iimi Onuma, Yusuke Iwata, Yue Zhou, Mai Nakada, Arisa Kondo, Hiroyuki Iwahara, Kanako Natori, Satoru Yokoyama, Kazuyasu Chihara, Kenji Takeuchi and 6 more

Abstract read
In one paragraph

Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Iimi OnumaDepartment of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Yusuke IwataDepartment of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Yue ZhouDepartment of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Mai NakadaDepartment of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Arisa KondoDepartment of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Hiroyuki IwaharaDepartment of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Kanako NatoriDepartment of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Satoru YokoyamaDepartment of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Kazuyasu ChiharaDepartment of Genome Science and Microbiology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Kenji TakeuchiDepartment of Genome Science and Microbiology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Kiyonao SadaDepartment of Genome Science and Microbiology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Tatsuhiko OzawaDepartment of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan; Center for Advanced Antibody Drug Development, University of Toyama, Toyama, Japan.
Mineyuki MizuguchiFaculty of Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Nobuyuki YamagishiLaboratory of Analytics for Biomolecules, Faculty of Pharmaceutical Science, Setsunan University, Osaka, Japan.
Michael KrachtRudolf Buchheim Institute of Pharmacology, Justus Liebig University, Giessen, Germany.
Hiroaki SakuraiDepartment of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, Japan. Electronic address: hsakurai@pha.u-toyama.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Src is a non-receptor tyrosine kinase that is overexpressed and highly activated in many cancers and is one of the key factors contributing to malignant transformation. According to current concepts, Src activity relies on tyrosine phosphorylation, and phospho(p) Y419 in the activation loop is often regarded as a marker of its activation. However, recent studies have shown that pY419 may contribute to substrate selection. Therefore, the mechanisms underlying Src activation other than classical tyrosine phosphorylation warrant further study. We herein demonstrated that Src phosphorylates a novel substrate, TAB1, directly at Y481 in the TAK1-binding domain, changing the TAK1-TAB1 interaction. p38 enhances Src-mediated TAB1 phosphorylation through the direct phosphorylation of Src at N-terminal S75. Moreover, the mode of substrate recognition by the SH2 domain of Src is different in TAB1 than in FAK, a known SH2-dependent substrate. The present results identify a novel non-canonical Src activation mechanism based on serine phosphorylation and suggest pY481-TAB1 and pS75-Src as improved markers of Src activation, thereby offering alternative modes for assessing the Src activation status of Src-dependent cancers before and during targeted therapy.

Indexed as

Adaptor Proteins, Signal Transducingp38 Mitogen-Activated Protein Kinasessrc-Family KinasesTyrosineAnimalsEnzyme ActivationHumansPhosphorylationAdaptor Proteins, Signal Transducingp38 Mitogen-Activated Protein Kinasessrc-Family KinasesTAB1 protein, humanTyrosineFAKp38srcTAB1TAK1tyrosine kinase

Identifiers

PMID41581886
PMCPMC12925544

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.